Dedicare (DEDI) Q4 2024 earnings summary

Executive summary

• 2024 was a challenging year with weak progress, especially in Q4, as all markets experienced declining demand and intensified competition, particularly in healthcare staffing.

• Net sales fell 12.7% year-over-year to SEK 1,719.7 million, with EBITA margin dropping to 4.0% from 8.2% the previous year.

• Cost-saving measures generated annual savings of SEK 16 million, and the group remains financially stable with an equity/assets ratio of 47.6%.

Financial highlights

• Q4 net sales: SEK 389.0 million (down 16.2% YoY); full-year net sales: SEK 1,719.7 million (down 12.7% YoY).

• Q4 EBITA: SEK 19.5 million (down 53.1% YoY); full-year EBITA: SEK 69.3 million (down 57.2% YoY).

• Adjusted EBITA for non-recurring items: SEK 12.8 million in Q4, SEK 73.3 million for the year.

• Q4 profit after financial items: SEK 17.7 million; full-year: SEK 59.7 million.

• Basic EPS: SEK 1.51 in Q4, SEK 4.92 for the year.

• Proposed dividend: SEK 2.50 per share, 50.8% of net profit.

Outlook and guidance

• Market conditions are expected to remain challenging in 2025, especially in Swedish healthcare staffing.

• The group is focusing on operational efficiency and growth in life science, where demand is rising.

• The cost base is lower entering 2025 due to restructuring and efficiency measures.